Ascendis Pharma A/SASNDNASDAQ

Revenue (LTM)

$692M

+90.2% YoY

Net Income (LTM)

$-219M

+42.1% YoY

Free Cash Flow

$44M

Revenue CAGR (5Y)

+150.9%

Marginsimproving

FCFTurned positive

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	8	51↑557.9%	267↑421.2%	364↑36.3%	692↑90.2%
Gross Profit	4	39↑817.4%	222↑469.5%	319↑43.7%	589↑84.3%
Operating Income	-452	-562↓24.4%	-456↑18.9%	-279↑38.8%	-131↑53.0%
Net Income	-384	-583↓52.0%	-481↑17.4%	-378↑21.5%	-219↑42.1%
EBITDA	-365	-529↓45.1%	-411↑22.3%	-290↑29.5%	-114↑60.7%
EPS Diluted	-7.00	-10.40↓48.6%	-8.55↑17.8%	-6.53↑23.6%	-3.62↑44.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	446	445↓0.3%	392↓11.8%	560↑42.7%	616↑10.1%
Total Current Assets	806	923↑14.6%	703↓23.9%	1,061↑51.0%	1,109↑4.5%
Total Assets	1,085	1,090↑0.4%	826↓24.2%	1,179↑42.9%	1,302↑10.4%
Total Current Liabilities	100	717↑614.2%	737↑2.8%	908↑23.3%	1,069↑17.7%
Total Liabilities	201	826↑310.6%	971↑17.5%	1,285↑32.3%	1,465↑14.0%
Total Equity	884	263↓70.2%	-146↓155.3%	-106↑27.4%	-163↓54.0%
Total Debt	210	618↑194.2%	743↑20.3%	857↑15.3%	871↑1.7%
Net Debt	-236	173↑173.1%	351↑103.1%	297↓15.3%	256↓13.9%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-418	-496↓18.7%	-467↑5.7%	-306↑34.5%	52↑116.9%
Capital Expenditure	-24	-14↑40.2%	-2↑83.1%	-1↑41.6%	-8↓471.1%
Free Cash Flow	-442	-510↓15.5%	-470↑7.9%	-308↑34.5%	44↑114.2%
Stock-Based Comp	67	64↓4.0%	67↑3.9%	96↑43.3%	0
Net Change in Cash	-138	-2↑98.9%	-53↓3406.9%	167↑418.2%	123↓26.7%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance